抗菌疗法与冾当的手术疗法一样,在弥漫性腹膜炎的治疗上占有重要地位。腹膜炎患者由于病原体结构的变化即对大多数抗菌药物产生自发或获得性耐药性的条件致病菌的分离率升高,机体在免疫性防御功能降低的基础上发病,以及播散性炎症过程中的药代动力学特点,所以给用药方案的制定造成困难。在腹膜炎具有危及生命的并发症——感染-中毒性休克患者的治疗上,抗菌疗法的意义更为重大。腹膜炎患者此种并发症的发生率为30%-39%,而死亡率竟高达60%。为了有效的治疗并发感染-中毒性休克的弥漫性 Antimicrobial therapy, like the appropriate surgical treatment, plays an important role in the treatment of diffuse peritonitis. Patients with peritonitis due to changes in the structure of the pathogen that most of the antibacterial drugs produce spontaneous or acquired resistance to the conditions of pathogens increased the isolation rate of the body on the basis of reduced immune defense and disseminated inflammatory processes In the pharmacokinetic characteristics, it is difficult to formulate a drug program. Antibacterial therapy is even more important in the treatment of patients with peritonitis, a life-threatening complication of infection-toxic shock. Peritonitis patients with this complication rate of 30% -39%, while the mortality rate as high as 60%. In order to effectively treat complicated infections - diffuse toxic shock